CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Cerevel Therapeutics Holdings, Inc. - CERE CFD

26.95
0.04%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.024068%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.001846%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 26.94
Open* 25.72
1-Year Change* -4.56%
Day's Range* 25.72 - 27.24
52 wk Range 19.86-41.46
Average Volume (10 days) 889.09K
Average Volume (3 months) 12.82M
Market Cap 3.57B
P/E Ratio -100.00K
Shares Outstanding 156.66M
Revenue N/A
EPS -2.32
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date May 8, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 29, 2022 26.95 1.81 7.20% 25.14 27.30 25.14
Jun 28, 2022 26.94 -0.93 -3.34% 27.87 29.13 26.80
Jun 27, 2022 28.99 0.89 3.17% 28.10 29.70 27.49
Jun 24, 2022 28.08 -0.17 -0.60% 28.25 29.09 27.63
Jun 23, 2022 28.54 3.28 12.98% 25.26 28.60 25.26
Jun 22, 2022 26.05 1.34 5.42% 24.71 26.24 24.71
Jun 21, 2022 25.15 -0.32 -1.26% 25.47 25.47 24.03
Jun 17, 2022 23.86 0.20 0.85% 23.66 24.42 23.16
Jun 16, 2022 22.85 -1.18 -4.91% 24.03 24.03 22.07
Jun 15, 2022 24.53 0.31 1.28% 24.22 24.87 23.33
Jun 14, 2022 24.22 0.64 2.71% 23.58 25.12 23.54
Jun 13, 2022 23.87 -0.71 -2.89% 24.58 24.67 23.20
Jun 10, 2022 25.82 -0.27 -1.03% 26.09 27.04 25.60
Jun 9, 2022 27.99 0.51 1.86% 27.48 28.92 27.48
Jun 8, 2022 28.49 1.30 4.78% 27.19 29.41 27.19
Jun 7, 2022 28.72 3.24 12.72% 25.48 28.84 25.48
Jun 6, 2022 25.86 -1.88 -6.78% 27.74 28.32 25.13
Jun 3, 2022 27.78 1.02 3.81% 26.76 28.51 26.76
Jun 2, 2022 26.98 1.06 4.09% 25.92 27.80 25.30
Jun 1, 2022 26.37 0.40 1.54% 25.97 26.76 25.02

Cerevel Therapeutics Holdings, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019
Total revenue 0 0 0
Operating Income -220.098 -149.116 0
Dilution Adjustment 0
Diluted Net Income -225.334 -148.271 0
Total Operating Expense 220.098 149.116
Selling/General/Admin. Expenses, Total 58.243 45.813
Research & Development 161.855 103.303
Interest Income (Expense), Net Non-Operating 0.157 0.224
Other, Net -5.393 -3.274
Net Income Before Taxes -225.334 -152.166
Net Income After Taxes -225.334 -152.142
Net Income Before Extra. Items -225.334 -152.142
Net Income -225.334 -152.142
Total Adjustments to Net Income 0 3.871
Income Available to Common Excl. Extra. Items -225.334 -148.271
Income Available to Common Incl. Extra. Items -225.334 -148.271
Diluted Weighted Average Shares 136.577 73.6433
Diluted EPS Excluding Extraordinary Items -1.64987 -2.01337
Diluted Normalized EPS -1.64987 -2.01337
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total revenue 0 0 0 0 0
Total Operating Expense 72.53 64.49 54.527 50.51 50.571
Selling/General/Admin. Expenses, Total 17.507 16.649 14.368 13.216 14.01
Research & Development 55.023 47.841 40.159 37.294 36.561
Operating Income -72.53 -64.49 -54.527 -50.51 -50.571
Interest Income (Expense), Net Non-Operating 0.295 0.119 0.013 0.01 0.015
Other, Net 3.941 5.316 -7.545 -2.739 -0.425
Net Income Before Taxes -68.294 -59.055 -62.059 -53.239 -50.981
Net Income After Taxes -68.294 -59.055 -62.059 -53.239 -50.981
Net Income Before Extra. Items -68.294 -59.055 -62.059 -53.239 -50.981
Net Income -68.294 -59.055 -62.059 -53.239 -50.981
Income Available to Common Excl. Extra. Items -68.294 -59.055 -62.059 -53.239 -50.981
Income Available to Common Incl. Extra. Items -68.294 -59.055 -62.059 -53.239 -50.981
Diluted Net Income -68.294 -59.055 -62.059 -53.239 -50.981
Diluted Weighted Average Shares 147.985 147.392 144.022 127.482 127.226
Diluted EPS Excluding Extraordinary Items -0.46149 -0.40067 -0.4309 -0.41762 -0.40071
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.46149 -0.40067 -0.4309 -0.41762 -0.40071
  • Annual
  • Quarterly
2021 2020 2019
Total Current Assets 578.017 390.56
Cash and Short Term Investments 565.688 383.623
Cash & Equivalents 193.018 383.623
Prepaid Expenses 11.6 6.777
Other Current Assets, Total 0.729 0.16
Total Assets 688.919 445.273
Property/Plant/Equipment, Total - Net 51.7 48.624
Property/Plant/Equipment, Total - Gross 54.266 48.706
Accumulated Depreciation, Total -2.566 -0.082
Other Long Term Assets, Total 6.933 6.089
Total Current Liabilities 42.538 29.548
Accounts Payable 11.298 4.993
Accrued Expenses 30.865 24.282
Notes Payable/Short Term Debt 0 0
Other Current Liabilities, Total 0.375 0.273
Total Liabilities 110.19 60.753
Total Long Term Debt 33.54 0
Other Liabilities, Total 34.112 31.205
Total Equity 578.729 384.52
Common Stock 0.015 0.013
Additional Paid-In Capital 1195.94 775.417
Retained Earnings (Accumulated Deficit) -616.244 -390.91
Total Liabilities & Shareholders’ Equity 688.919 445.273
Total Common Shares Outstanding 147.72 127.124
Short Term Investments 372.67
Long Term Investments 52.269
Long Term Debt 33.54
Other Equity, Total -0.986
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 553.55 578.017 675.029 331.782 349.811
Cash and Short Term Investments 542.944 565.688 669.676 327.06 343.287
Cash & Equivalents 91.764 193.018 669.676 327.06 343.287
Prepaid Expenses 10.004 11.6 5.257 4.597 6.362
Other Current Assets, Total 0.602 0.729 0.096 0.125 0.162
Total Assets 618.552 688.919 733.48 391.004 408.104
Property/Plant/Equipment, Total - Net 52.663 51.7 51.98 51.92 51.784
Property/Plant/Equipment, Total - Gross 56.299 54.266 53.526 52.552 51.876
Accumulated Depreciation, Total -3.636 -2.566 -1.546 -0.632 -0.092
Other Long Term Assets, Total 4.411 6.933 6.471 7.302 6.509
Total Current Liabilities 35.318 42.538 30.8 29.257 34.151
Accounts Payable 8.183 11.298 5.445 4.986 7.755
Accrued Expenses 26.442 30.865 24.928 23.939 26.241
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.693 0.375 0.427 0.332 0.155
Total Liabilities 97.053 110.19 104.4 97.117 68.068
Total Long Term Debt 28.324 33.54 38.612 32.242 0
Other Liabilities, Total 33.411 34.112 34.988 35.618 33.917
Total Equity 521.499 578.729 629.08 293.887 340.036
Common Stock 0.015 0.015 0.015 0.013 0.013
Additional Paid-In Capital 1207.36 1195.94 1186.79 789.004 781.914
Retained Earnings (Accumulated Deficit) -684.538 -616.244 -557.189 -495.13 -441.891
Total Liabilities & Shareholders’ Equity 618.552 688.919 733.48 391.004 408.104
Total Common Shares Outstanding 148.183 147.72 147.136 127.585 127.325
Long Term Debt 28.324 33.54 38.612 32.242
Other Equity, Total -1.334 -0.986 -0.533
Short Term Investments 451.18 372.67
Long Term Investments 7.928 52.269
  • Annual
  • Quarterly
2021 2020 2019
Net income/Starting Line -225.334 -152.142
Cash From Operating Activities -178.546 -117.802
Cash From Operating Activities 2.731 0.397
Non-Cash Items 28.516 16.236
Changes in Working Capital 15.541 17.707
Cash From Investing Activities -435.661 -18.892
Capital Expenditures -10.503 -18.892
Cash From Financing Activities 423.602 440.835
Financing Cash Flow Items -0.355 440.835
Net Change in Cash -190.605 304.141
Other Investing Cash Flow Items, Total -425.158
Issuance (Retirement) of Stock, Net 392.707
Issuance (Retirement) of Debt, Net 31.25
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -68.294 -225.334 -166.279 -104.22 -50.981
Cash From Operating Activities -67.648 -178.546 -125.802 -82.026 -36.418
Cash From Operating Activities 1.118 2.731 1.644 0.664 0.063
Non-Cash Items 4.935 28.516 27.551 14.084 6.377
Changes in Working Capital -5.407 15.541 11.282 7.446 8.123
Cash From Investing Activities -38.542 -435.661 -9.431 -8.243 -4.66
Capital Expenditures -2.197 -10.503 -9.431 -8.243 -4.66
Cash From Financing Activities 2.603 423.602 421.286 33.706 0.742
Issuance (Retirement) of Stock, Net 2.854 392.707 390.036 2.571 0.742
Net Change in Cash -103.587 -190.605 286.053 -56.563 -40.336
Financing Cash Flow Items -0.251 -0.355 0 -0.115
Issuance (Retirement) of Debt, Net 31.25 31.25 31.25
Other Investing Cash Flow Items, Total -36.345 -425.158
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Bain Capital Private Equity, LP Private Equity 38.704 60632356 0 2022-12-31 LOW
Pfizer Inc Corporation 17.4581 27349211 0 2022-08-16 MED
Fidelity Management & Research Company LLC Investment Advisor 14.5879 22852917 67107 2022-12-31 LOW
Perceptive Advisors LLC Private Equity 4.1567 6511727 0 2022-12-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.8476 6027510 164460 2022-12-31 LOW
T. Rowe Price Associates, Inc. Investment Advisor 3.027 4742044 1202 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.2049 3454078 288570 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.1858 3424220 704948 2022-12-31 LOW
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 1.8304 2867451 -445882 2022-12-31 LOW
Rock Springs Capital Management LP Hedge Fund 1.6 2506464 7316 2022-12-31 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 1.2806 2006068 4631 2022-12-31 MED
Invus Public Equities Advisors, LLC Investment Advisor 1.2128 1900000 -100000 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7686 1204108 69847 2022-12-31 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 0.7349 1151321 -231639 2022-12-31 LOW
Lord, Abbett & Co. LLC Investment Advisor 0.7159 1121566 35610 2022-12-31 MED
Hood River Capital Management LLC Investment Advisor 0.5896 923638 27066 2022-12-31 MED
Alkeon Capital Management LLC Investment Advisor/Hedge Fund 0.5716 895509 -87899 2022-12-31 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.4755 744853 7881 2022-12-31 LOW
Novalis LifeSciences LLC Private Equity 0.4043 633350 0 2022-03-31
Fidelity Institutional Asset Management Investment Advisor 0.3602 564215 34460 2022-12-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

500K+

Traders

92K+

Active clients monthly

$53M+

Monthly investing volume

$30M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Cerevel Therapeutics Holdings, Inc. Company profile

About Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company combines an understanding of disease-related biology and neurocircuitry of the brain with chemistry and central nervous system (CNS), receptor pharmacology to discover and design new therapies. The Company is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, epilepsy and Parkinson’s disease. The Company’s product candidate includes CVL-231, Darigabat, Tavapadon, CVL-871 and CVL-936. The Company’s product candidate CVL-231 for the treatment of schizophrenia. Its Darigabat for the treatment of both epilepsy and anxiety. Its Tavapadon is a dopamine D1/D5 partial agonist for the treatment of early- and late-stage Parkinson’s disease. Its product candidate CVL-871 for the treatment of dementia-related apathy. Its CVL-936 for the treatment of substance use disorder (SUD).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cerevel Therapeutics Holdings Inc revenues was not reported. Net loss applicable to common stockholders increased 52% to $225.3M. Higher net loss reflects Research and development increase of 57% to $161.9M (expense), General and administrative increase of 27% to $58.2M (expense), Other income (expense), net increase of 65% to $5.4M (expense).

Industry: Bio Therapeutic Drugs

222 Jacobs Street
Suite 200
CAMBRIDGE
MASSACHUSETTS 02141
US

Income Statement

  • Annual
  • Quarterly

People also watch

XRP/USD

0.43 Price
-4.880% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00382

Oil - Crude

67.15 Price
-3.380% 1D Chg, %
Long position overnight fee -0.0169%
Short position overnight fee -0.0050%
Overnight fee time 21:00 (UTC)
Spread 0.03

US100

12,663.60 Price
-0.670% 1D Chg, %
Long position overnight fee -0.0241%
Short position overnight fee 0.0018%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

1,995.29 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0176%
Short position overnight fee 0.0094%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading